Unknown OBSERVATIONAL NCT05663177

Almonertinib Plus Metronomic Oral Vinorelbine

Almonertinib Plus Metronomic Oral Vinorelbine Beyond Limited Progression on Third-generation TKI in EGFR-mutant Advanced NSCLC，an Observational Study

Sponsor: Fujian Cancer Hospital

Conditions EGFR NSCLC Third-generation TKI

Interventions Almonertinib and metronomic oral vinorelbine

Updated 4 times since 2023 Last updated: Dec 21, 2022 Started: Dec 20, 2022 Primary completion: Dec 20, 2023 Completion: Jun 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05663177, this observational or N/A phase trial focuses on EGFR and NSCLC and remains ongoing. Sponsored by Fujian Cancer Hospital, it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Jan 2023 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fujian Cancer Hospital

Data source: Fujian Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.